about
Aspergillus citrinoterreus, a new species of section Terrei isolated from samples of patients with nonhematological predisposing conditionsIncreasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates.PERMANENT GENETIC RESOURCES: Development of 52 new polymorphic SSR markers from cherimoya (Annona cherimola Mill.): transferability to related taxa and selection of a reduced set for DNA fingerprinting and diversity studies.Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care centerMapping genetic diversity of cherimoya (Annona cherimola Mill.): application of spatial analysis for conservation and use of plant genetic resourcesEvaluation of MycAssay™ Aspergillus for diagnosis of invasive pulmonary aspergillosis in patients without hematological cancer.[Use of molecular typing tools for the study of hospital outbreaks of candidemia].Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole.Microsatellite (STRAf) genotyping cannot differentiate between invasive and colonizing Aspergillus fumigatus isolates.Molecular epidemiology of Aspergillus fumigatus: an in-depth genotypic analysis of isolates involved in an outbreak of invasive aspergillosis.Rapid detection and identification of Aspergillus from lower respiratory tract specimens by use of a combined probe-high-resolution melting analysis.Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species.Endemic genotypes of Candida albicans causing fungemia are frequent in the hospitalIs azole resistance in Aspergillus fumigatus a problem in Spain?Comparison between the EUCAST procedure and the Etest for determination of the susceptibility of Candida species isolates to micafungin.Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.Scope and frequency of fluconazole trailing assessed using EUCAST in invasive Candida spp. isolates.Micafungin is more active against Candida albicans biofilms with high metabolic activity.Frequency of the Paradoxical Effect Measured Using the EUCAST Procedure with Micafungin, Anidulafungin, and Caspofungin against Candida Species Isolates Causing Candidemia.Sputum and bronchial secretion samples are equally useful as bronchoalveolar lavage samples for the diagnosis of invasive pulmonary aspergillosis in selected patients.Candida guilliermondii Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia.In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations.The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.Comparison of the antifungal activity of micafungin and amphotericin B against Candida tropicalis biofilms.Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.Risk factors for late recurrent candidaemia. A retrospective matched case-control study.Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production.Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia.Clusters of patients with candidaemia due to genotypes of Candida albicans and Candida parapsilosis: differences in frequency between hospitals.Production of biofilm by Candida and non-Candida spp. isolates causing fungemia: comparison of biomass production and metabolic activity and development of cut-off points.In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.Invasive pulmonary aspergillosis in heart transplant recipients: two radiologic patterns with a different prognosis.Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia.Is catheter-related candidemia a polyclonal infection?Does identification to species level provide sufficient evidence to confirm catheter-related fungemia caused by Candida albicans?Growth of Aspergillus in blood cultures: proof of invasive aspergillosis in patients with chronic obstructive pulmonary disease?Genotyping of Aspergillus fumigatus Reveals Compartmentalization of Genotypes in Disseminated Disease after Invasive Pulmonary Aspergillosis.Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B.Fungaemia caused by rare yeasts: incidence, clinical characteristics and outcome over 10 years.
P50
Q30877963-EB2A0A55-CC32-4AA9-9FC1-95D1C347BF3AQ33773267-62F7D1D6-B7C4-4BEA-89CC-BE7C04D95039Q33902800-0478DE8D-2608-4D52-97E5-78BEABF02973Q34058322-62E96276-B011-485F-A349-A37E36B1FD2AQ34130704-64A9F76D-AED7-4E90-93A6-4E120C05DFDAQ34688953-AA82308D-E205-4061-BF2D-A920B6B04123Q34781161-E185850B-1CBF-4770-9B6D-847316BF8344Q34933141-12C1394E-E4A4-4DA6-B98E-CD6A13BBF541Q34983239-4EB8976F-684C-4668-9CB2-976206DAD0DCQ35273490-6AC02CD4-AC88-4B80-BBAB-DC7F29846C30Q36276996-92A7A53A-5839-41B2-971B-B870B0D1D96BQ36933366-DB09893B-661A-4C5A-9BA2-AF7E3AD84FF6Q36971170-7CEA3860-AFF2-45F7-A12F-4F87FC7CCD86Q37026702-637A0BF8-D067-4B6D-9053-5854D15D3CBEQ37263358-C268A5A6-EE4D-441F-9359-D37C10836F1DQ37643602-02652A83-FEB9-4965-AB4C-96EA80A93089Q38869418-DD9316FC-2A0C-418E-BA08-40F5F4C4F1FAQ39173771-24319409-5934-4C20-ABBC-6D32900CEA77Q39230127-9C018B24-3192-45AB-85E0-13F66503EDACQ40171946-2CB457AD-5E12-4752-8F6A-F4F288CFB5EAQ40239343-D7AB3B38-30F9-4FFD-A67F-179B14F5564FQ40325403-1319C1DD-9D5A-48B6-ABC4-8F10B04B6BD7Q40340923-4C639C13-7132-4355-8F66-6F87DA32EB73Q40441738-8F05253A-8E09-45A3-B97F-E209A31652AAQ40687144-3DF268FA-9BE4-47B4-8591-7F35399E601EQ40842732-BF5697A1-DBB2-4AA2-B06D-14BC870FD559Q40918232-32B964C4-FBA8-4D43-98BA-5C742E821D14Q40920367-00ED5E28-89AF-4F43-8DBE-ADBEBF095BDEQ41017112-A3BEA09A-2348-41F8-BB92-F94AD9DFC40CQ41325938-278FD685-DC65-4B41-BF46-84E8969E0BA1Q41738290-A090212B-A164-4DED-B33D-7EF926DD83EEQ41790396-76D890B9-B794-4229-9927-77313545A86FQ42206624-0E731C53-D93C-4BE1-8E63-82628BEDE2F3Q42222513-C6D3AE75-C30A-4B53-A18D-8B65F4E0C105Q42224230-C329BAFF-8650-424F-BBCD-4AC360550A75Q42256837-1A35924B-BE47-4210-87D4-EB2BE29154BFQ42276893-A2BE0059-0C79-48DF-80B3-2B9E2BA8F514Q42331366-89521320-221E-4F2B-8B2A-93CD1264C1EDQ46176826-4D817E02-FD7A-475E-AB35-B7FB62B8BBC5Q46244854-A520CBB4-B278-454D-B217-E2B689D78A72
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pilar Escribano
@ast
Pilar Escribano
@en
Pilar Escribano
@es
Pilar Escribano
@nl
Pilar Escribano
@sl
type
label
Pilar Escribano
@ast
Pilar Escribano
@en
Pilar Escribano
@es
Pilar Escribano
@nl
Pilar Escribano
@sl
prefLabel
Pilar Escribano
@ast
Pilar Escribano
@en
Pilar Escribano
@es
Pilar Escribano
@nl
Pilar Escribano
@sl
P1053
M-2387-2014
P106
P21
P31
P3829
P496
0000-0001-6254-4570
P569
2000-01-01T00:00:00Z